Veracyte

Veracyte Rule of 40

The Rule of 40 of Veracyte (VCYT) as of Nov 3, 2026 is 30.35 %. In the previous year, Rule of 40 was 27.08 % — a change of 12.06% (higher).

Rule of 40

30.35 %

YoY

12.06%

Last updated:

Rule of 40 of Veracyte is 2025 30.35 % . Rule of 40 of Veracyte was 2024 27.08 % . It decreases by 12.06% higher compared to the previous year.

The Veracyte Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
5.01 USD
Jan 1, 2019
18.26 USD
Jan 1, 2020
-32.52 USD
Jan 1, 2021
49.54 USD
Jan 1, 2022
21.23 USD
Jan 1, 2023
-2.01 USD
Jan 1, 2024
27.08 USD
Jan 1, 2025
30.35 USD
The Veracyte Rule of 40 history
YEARRule of 40YoY
30.35 %+12.06%
27.08 %-1,449.91%
-2.01 %-109.45%
21.23 %-57.13%
49.54 %-252.33%
-32.52 %-278.13%
18.26 %+264.46%
5.01 %-118.01%
-27.81 %+123.09%
-12.47 %-67.18%
-37.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

Rule of 40 of Veracyte is 30.35 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Veracyte since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Veracyte

All Key Metrics — Veracyte